Travis Thompson
Oral and Maxillofacial Pathology · Jupiter, FLNPI 1255302105
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.4% of the total across 72 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Zimvie Inc. accounts for 78.5% of it on its own, with 4 other manufacturers making up the rest.
Across 72 payments — averaging $38.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Zimvie Inc.$2K
- Zimmer Biomet$472
- Straumann USA LLC$84
- Nobel Biocare USA$27
- Pacira Pharmaceuticals Incorporated$17
What the payments were for
- Food & beverage$2,69996%
- Education$1004%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Zimvie Inc. | 55 | $2,198 |
| Zimmer Biomet | 13 | $472 |
| Straumann USA LLC | 2 | $84 |
| Nobel Biocare USA | 1 | $27 |
| Pacira Pharmaceuticals Incorporated | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few oral and maxillofacial pathology providers in Floridato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Amoxicillin | 309 | $987 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 130 | $680 |
| Chlorhexidine Gluconate | 104 | $422 |
| Tramadol Hcl-AcetaminophenTramadol Hcl/Acetaminophen | 82 | $273 |
| Clindamycin Hcl | 38 | $258 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 21 | $191 |
| Azithromycin | 21 | $102 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 24 | $97 |
| Tramadol Hcl | 38 | $67 |
Paid to pharmacies, not to this prescriber.
Other oral and maxillofacial pathology in Jupiter
- Paul WeinsteinJupiter$2K
- Todd SawischFort Lauderdale$448K
- Harold RichmanAventura$14K
- Harley RichardsLakeland$13K
- Kenyon FortSt Petersburg$3K
- Luis AliceaOrlando$3K
- Andrew SlavinWest Palm Beach$1K
- Scott FarberOrlando$264
- Patricia ScottPort Charlotte$224
- Lina MejiaDavie$154
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.